

Cost Effectiveness of Treatments After Failure of a First-Line Hypomethylating Agent in Myelodysplastic Syndromes (MDS)

Christopher R. Cogle, MD¹; Sudipto Mukherjee, MD, MPH²; Moira E. Lawrence, PhD³; Tom McKearn, MD, PhD³; Rita Percy³; Michael E. Petrone, MD, MPH³; Scott Megaffin³; Ayanna M. Anene, BS⁴; Jesse Ortendahl, MS⁴; Dorothy Romanus, RPh, PhD⁴; Tanya G.K. Bentley, PhD⁴

¹University of Florida; ²Cleveland Clinic; ³Onconova Therapeutics, Inc.; ⁴Partnership for Health Analytic Research, LLC

BACKGROUND & OBJECTIVE

Background

- Myelodysplastic syndromes (MDS) are a group of disorders characterized by cytopenias and multiple genetic abnormalities¹
- More than 86% of patients with MDS are 60 years or older²
- High-risk elderly MDS patients are typically treated first with hypomethylating agents (HMAs)³; however these are not curative and require patients to consider 2nd line treatments⁴
- Selecting the optimal 2nd-line treatment in MDS patients is challenging due to a lack of therapeutic options and little data regarding the risks and benefits of existing disease management

Objective

- Evaluate the clinical outcomes, economic impact, and cost effectiveness of currently available treatment options for MDS patients who failed 1st-line HMA therapy

METHODS


Overview

- Study type: Markov cohort model
- Patient population: MDS patients who progressed on or failed previous treatment with HMAs
- Time-horizon: Lifetime
- Model cycle length: 4 weeks
- Perspective: Payer
- Model strategies:
 - Best supportive care (BSC)
 - Low-intensity chemotherapy (LIC) with BSC
 - High-intensity chemotherapy (HIC) with BSC
 - Switching HMA treatment with BSC
 - Hematopoietic cell transplant (HCT) with BSC
- Clinical and cost parameters were selected from published sources; when published data were not available, inputs were derived based on expert opinion
- Results were reported as:
 - Costs (2014 USD)
 - Survival in life years (LYs)
 - Incremental cost-effectiveness ratio (ICER)

Model Structure

- Hypothetical cohorts of patients who had failed a 1st-line HMA were simulated during each 4-week cycle
- After entering the model at the time of initiation of 2nd-line treatment, patients could:
 - Experience a treatment- or disease-related adverse event
 - Discontinue treatment
 - Progress to acute myeloid leukemia (AML)
 - Die

Figure 1. Model Schematic^{a,b}



^a The schematic depicts a Markov model that simulates patients through 4-week cycles for their lifetime, and estimates survival and payer costs.

^b Red circles represent model health states.

^c Starting population represents MDS patients after failure of initial HMA therapy.

^d 2nd-line treatment strategies/comparators are: BSC, HMA, LIC, HIC, or HCT.

^e Adverse events include thrombocytopenia, anemia, and neutropenia.

Table 1. Treatment Cost Estimates

Treatment Costs	Cost \$US 2014 ^a (per 4-week cycle)	Source
BSC ^b	\$1,749	5
2 nd HMA ^c	\$4,038	
LIC ^c	\$56	6-8
HIC ^c	\$38,554	
HCT (per patient)	\$161,475	9
AML	\$12,470	10

^a Assuming 1.8m² BSA. Wastage included. The least expensive generic product was selected when identical package sizes of the same drug were available.

^b Includes costs of hospitalization, physician visits, supportive care medication, lab tests

^c Product administration costs added on a per-cycle basis.

Table 2. Clinical Parameters

MDS Treatment	Value	Source
Median overall survival (months)		
BSC	4.0	11
2 nd HMA	6.0	12, Expert Opinion ^a
LIC	7.3	
HIC	8.9	11
HCT	19.0	
Median treatment duration (number of four-week cycles)		
HMA	4.0	12
LIC	4.0	Expert Opinion
HIC	2.5	Expert Opinion
Proportion of Patients Progressing to AML		
All Strategies	35%	Expert Opinion

^a Estimated based on consultations with various practicing clinical oncologists.

Table 3. Adverse Event Utilization Rates and Costs

Utilization Rates	Utilization (per 4-week cycle)	Source
Red Blood Cells (units per patient) ^{a,b}		
BSC	5.2	
2 nd HMA	2.8	
LIC	5.4	
HIC	5.0	
HCT	9.0	13, Expert opinion
Platelet (units per patient) ^b		
BSC	1.2	
2 nd HMA	2.2	
LIC	3.8	
HIC	5.0	
HCT	9.0	
Growth Factors (all strategies, proportion of patients requiring a growth factor)		
Filgrastim	0.4	
Epoetin	0.5	Data on file ^c
Adverse Event Costs		
Red Blood Cells (per transfusion) ^d	\$789	
Platelets (per transfusion) ^d	\$633	
Growth Factors (per patient, per model cycle) ^d		
Filgrastim	\$484	14, 15
Epoetin	\$300	

^a Blood requirements and growth factor use incorporated into the model for costing purposes, to reflect resources utilized to treat thrombocytopenia, anemia, and neutropenia.

^b Blood requirements for BSC, HMA and LIC based on Levy 2014, and doubled based on expert opinion. Values for HIC and HCT based solely on expert opinion.

^c Burden of illness analysis of OptumInsight data to estimate healthcare utilization among 2nd-line MDS patients, conducted by PHAR, LLC, 2014.

^d For costing, model assumed patients can receive up to 2 units in a single infusion.¹⁴

RESULTS

- Treating patients who had failed 1st-line HMA with BSC was the least expensive option (\$55,343 per person) but provided the shortest survival: 0.48 years.
- Switching patients to another HMA for 2nd-line treatment increased costs to \$84,625 and extended survival only modestly.
- HCT patients had the highest survival (2.26 years) and lifetime costs (\$492,359).
- Compared with BSC, the ICER for LIC was \$87,343/LY gained, while HIC and HCT had ICERs of \$284,303 and \$291,375/LY, respectively.
- The strategy of switching patients to a second HMA was removed during the calculation of ICERs due to extended dominance since the next-best strategy, namely LIC, provided greater clinical benefit and had a more attractive ICER.

Table 4. Results: All Strategies

Strategy	Lifetime Costs (\$)		Mean Survival (years)		ICER (\$/LY)
	Absolute	Difference ^a	Absolute	Difference ^a	
BSC	\$55,343	-	0.48	-	-
2 nd HMA	\$84,625	\$29,282	0.72	0.24	Dominated ^b
LIC	\$89,877	\$5,252	0.88	0.15	\$87,343
HIC	\$146,519	\$56,642	1.08	0.20	\$284,303
HCT	\$492,359	\$345,840	2.26	1.19	\$291,375

^a Difference compared to row above.

^b Dominated indicates there is another strategy (namely LIC) that provides greater clinical benefit with a more attractive cost effectiveness ratio.

CONCLUSION

- For MDS patients who relapsed after, failed to respond to, or progressed during administration of a 1st-line HMA, subsequent alternative active treatments:
 - Provide some survival benefit
 - Substantially increase costs and treatment-related morbidity
- The significantly greater cost and accompanying increase in morbidity associated with more aggressive approaches (HIC and transplant) could be interpreted as inefficient according to current societal standards.
- In addition, the use of treatments such as transplant may be limited due to the risk of transplant-related adverse events, patient health status, and the availability of a suitable stem cell donor.
- These findings expose an unmet need among MDS patients after failure of 1st-line HMA therapy.
- The development of lower-cost, highly-efficacious 2nd-line MDS treatment options which do not cause an increase in cytopenia would benefit:
 - Clinical decision-making
 - Patient outcomes
 - Healthcare resource allocation

Limitations

- Further studies are needed to measure the clinical impact of 2nd-line MDS treatments as there were limited data available to inform the clinical parameters used in this analysis.
- This analysis did not consider the impact of treatments on quality of life. We intend to explore this in subsequent analyses.

REFERENCES

- Greenberg J Natl Compr Canc Netw 2013;
- Cogle Blood 2011;
- Wang Leuk Res 2011;
- Steensma Hematol Oncol Clin North Am 2010;
- Pan Clin Ther 2010;
- Fenaux Lancet Oncol;
- National Comprehensive Cancer Network (NCCN) 2014;
- PriceRx@ Wolters Kluwer 2014;
- Majhail Bone Marrow Transplant 2013;
- Lang Drugs Aging 2005;
- Prébet J Clin Oncol 2011;
- Borthakur Leuk Lymphoma 2008;
- Levy Curr Oncol 2014;
- Gidwani J Med Econ 2012;
- Goss Cancer Control 2006.